Xagenic Looks To Launch Point-of-Care Molecular Dx Platform Targeting Infectious Disease
This article was originally published in The Gray Sheet
The start-up has created the Xagenic X1 platform to run molecular diagnostic tests in a physician's office in about 20 minutes instead of sending samples out to a lab. The company plans to address chlamydia and gonorrhea first, and to establish a presence in the sexually transmitted infections, women's health, and urgent and primary care markets.
You may also be interested in...
Xagenic Inc.’s Amplified Redox Assay (AuRA) POC system utilizes chip-based arrays of microelectrodes to test samples for the presence of telltale nucleic acid strands. Because it is chip-based, it should be simple to run multiple tests on a single chip, and no sample extraction or preparation is needed to run the test.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.